The efficacy and safety of topical antifungal miconazole cream in the treatment of corneal fungal infection, (Candida albicans)

Miconazole is a broad-spectrum antimycot agent that has been proven to be effective in secondary mycoses caused by Candida albicans, a fungus resembling yeast causing fungal infection in man and animals. The study determined the safety and efficacy of topical antifungal miconazole in 21 rabbits. The sample population was divided into three groups treated once, twice and thrice daily. Administration was done topically in a week with 3 hours daytime interval. Gross examination based on the percentage of adverse reactions and level of inhibation showed that once a day treatment was the safety and inhibited best the pathogenic activity of the fungus. Slow inhibition was attributed to the excessive use of miconazole observed in twice and trice daily treatment that produced edema and opacity due to hypersensitivity reaction. Finally, therapeutic safety, as measured by the spread between the effective dose and the dose at which slow adverse reactions begin to appear was significantly justified by the inhibitory performance of miconazole